Fig. 3 | Scientific Reports

Fig. 3

From: Changes in interictal cerebral blood flow observed in migraine patients who respond to anti-calcitonin gene-related peptide therapy

Fig. 3

Changes in CBF measured on ASL before and after anti-CGRP therapy in each group. White bars indicate CBF before treatment and black bars indicate CBF after treatment. (A) Group CHP and CBF-. (B) Group NoCHP and CBF-. (C) Group NoCHP and CBF+. (D) Group ConstantCBF. ACA, anterior cerebral artery; AM, anterior part of the middle cerebral artery territory; PM, posterior part of the middle cerebral artery territory; PCA, posterior cerebral artery; THA, thalamus. Compared with the other groups, Group CHP and CBF- (A) shows significantly greater pretreatment CBF in all ROIs, whereas CBF after anti-CGRP therapy is significantly decreased in all ROIs. CBF of post-CGRP therapy is significantly lower in Group NoCHP and CBF- (B) than in the other groups for all ROIs and is below normal value in all regions. Only Group NoCHP and CBF+ (C) show increased CBF after treatment. As a result, CBF in both Group CHP and CBF- (A) and Group NoCHP and CBF+ (C) becomes approximately equivalent for each ROI. Group ConstantCBF (D) before and after anti-CGRP therapy shows no significant changes in any ROI.

Back to article page